Myriad Genetics Inc income statement

In fiscal 2025, Myriad Genetics Inc reported revenue of $825m, down 1.6% on the year before, operating income of −$387m (a -47.0% margin) and net income of −$366m, or −$3.95 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Myriad Genetics Inc: income statement, annual
Fiscal year	2009Jun 2009	2010Jun 2010	2011Jun 2011	2012Jun 2012	2013Jun 2013	2014Jun 2014	2015Jun 2015	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	327	363	402	496	613	778	723	754	771	744	851	639	691	678	753	838	825	807
Cost of revenue	43	44	46	51	64	96	133	133	145	—	—	—	—	202	236	252	248	251
Gross profit	283	318	356	445	549	682	590	621	626	—	—	—	—	476	517	585	577	555
Research and development	18	22	28	43	54	68	76	71	74	71	86	77	82	85	89	113	107	106
Selling, general and administrative	139	161	170	208	252	327	366	359	440	435	557	507	538	515	573	—	—	—
Selling and marketing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	284	281	296
General and administrative	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	276	257	244
Operating income	126	135	158	180	228	274	134	153	44	122	8	−232	−191	−141	−257	−124	−387	−99
Interest expense	—	—	—	—	—	—	0	0	6	3	12	11	7	3	3	3	11	16
Income before tax	136	141	160	185	233	278	134	156	36	120	0	−223	−57	−141	−262	−124	−395	−112
Income tax	0	−11	59	72	86	102	55	39	19	−13	−4	−24	−30	−29	1	4	−29	1
Net income	85	152	101	112	147	176	80	117	17	133	5	−200	−27	−112	−263	−127	−366	−113
Diluted EPS	$0.86	$1.54	$1.10	$1.30	$1.77	$2.25	$1.07	$1.60	$0.25	$1.85	$0.06	−$2.69	−$0.35	−$1.39	−$3.18	−$1.41	−$3.95	−$1.20
Diluted shares (average)	99m	99m	92m	86m	83m	78m	75m	73m	69m	72m	76m	74m	78m	81m	83m	91m	93m	94m
EBITDA	136	142	165	189	237	288	159	180	92	176	81	−160	−128	−88	−196	−62	−334	−64

US$ millions unless shown otherwise. Fiscal quarters.

Myriad Genetics Inc: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	213	211	196	213	206	210	200	191
Cost of revenue	64	60	62	61	62	63	63	64
Gross profit	150	151	134	152	144	147	138	127
Research and development	29	32	28	26	28	26	27	25
Selling, general and administrative	139	—	—	—	—	—	—	—
Selling and marketing	—	72	69	72	71	69	74	83
General and administrative	—	64	67	67	68	56	62	58
Operating income	−20	−39	−29	−329	−23	−6	−31	−39
Interest expense	1	1	1	2	4	4	4	4
Income before tax	−21	−39	−29	−331	−26	−9	−34	−43
Income tax	1	3	−29	−0	1	−1	0	1
Net income	−22	−43	−0	−331	−27	−8	−34	−43
Diluted EPS	−$0.24	−$0.47	$0.00	−$3.57	−$0.29	−$0.07	−$0.36	−$0.46
EBITDA	−15	−24	−15	−324	−19	7	−18	−34

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IRTC vs MYGN MYGN vs OFIX ATEC vs MYGN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Myriad Genetics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Myriad Genetics Inc.